Immunitybio Inc banner

Immunitybio Inc
NASDAQ:IBRX

Watchlist Manager
Immunitybio Inc Logo
Immunitybio Inc
NASDAQ:IBRX
Watchlist
Price: 7.38 USD -8.55% Market Closed
Market Cap: $7.6B

Wall Street
Price Targets

IBRX Price Targets Summary
Immunitybio Inc

Wall Street analysts forecast IBRX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for IBRX is 13.06 USD with a low forecast of 7.07 USD and a high forecast of 25.2 USD.

Lowest
Price Target
7.07 USD
4% Downside
Average
Price Target
13.06 USD
77% Upside
Highest
Price Target
25.2 USD
241% Upside
Immunitybio Inc Competitors:
Price Targets
MRVL
Marvell Technology Group Ltd
20% Upside
VIAV
Viavi Solutions Inc
-23% Downside
RCKT
Rocket Pharmaceuticals Inc
68% Upside
WASH
Washington Trust Bancorp Inc
8% Upside
WINA
Winmark Corp
30% Upside
APA
APA Corp (US)
-37% Downside

Revenue
Forecast

60% / Year
Past Growth
122% / Year
Estimated Growth
Estimates Accuracy
23%
Average Beat
60% / Year
Past Growth
122% / Year
Estimated Growth
Estimates Accuracy
23%
Average Beat

For the last 11 years the compound annual growth rate for Immunitybio Inc's revenue is 60%. The projected CAGR for the next 3 years is 122%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-76%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-76%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is IBRX's stock price target?
Price Target
13.06 USD

According to Wall Street analysts, the average 1-year price target for IBRX is 13.06 USD with a low forecast of 7.07 USD and a high forecast of 25.2 USD.

What is Immunitybio Inc's Revenue forecast?
Projected CAGR
122%

For the last 11 years the compound annual growth rate for Immunitybio Inc's revenue is 60%. The projected CAGR for the next 3 years is 122%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett